Senior Director, Clinical Operations
Kymera Therapeutics
August 21, 2026
Remote friendly (Greater Boston)
United States
Clinical Research and Development
How you’ll make an impact:
Senior Director, Clinical Operations responsible for overseeing all clinical operations for the Phase 3 program of immunology program KT-621; drives cross-functional strategy and operational execution through regulatory approval; hires and manages teams internally, at clinical sites, and with vendors.
- Lead and oversee strategic planning, implementation, and execution of late-stage clinical trials per timelines, budget, and quality standards (including ICH GCP and local regulations)
- Develop and manage program project plans (protocols, budgets, timelines, enrollment, risk mitigation)
- Collaborate cross-functionally with Clinical Development, Regulatory Affairs, Biostatistics, and Program Leadership
- Provide operational expertise and strategic input into Clinical Development Plans (CDP)
- Ensure robust Phase 3 operational strategies (country/site mix, PR&R and Site Engagement, vendor strategy, risk-based and site monitoring)
- Serve as point of contact for CROs/vendors; oversee performance and adherence to contracts, timelines, and quality
- Ensure compliance with regulatory requirements, ICH-GCP, and company SOPs
- Support inspection readiness; guide Clinical Study Leads for inspections
- Contribute to/review clinical study documents (IB, IND, protocols, clinical study reports, NDA/MAA sections, IND/NDA updates, safety reports)
- Hire, train, and develop the KT-621 Phase 3 Clinical Operations team
Skills and experience you’ll bring:
- BA/BS, preferably health-related
- 12+ years clinical operations experience (pharma/biotech)
- Experience building/leading high-performing clinical operations teams
- Global regulatory/compliance expertise (US CRF, EU CTD, ICH GCP)
- Manage competing priorities in a fast-paced, high-pressure environment
- Strong communication, interpersonal, and problem-solving skills
Compensation:
- Anticipated base salary range: $235,000–$330,000; eligibility for annual bonus, equity participation, and comprehensive benefits.
Senior Director, Clinical Operations responsible for overseeing all clinical operations for the Phase 3 program of immunology program KT-621; drives cross-functional strategy and operational execution through regulatory approval; hires and manages teams internally, at clinical sites, and with vendors.
- Lead and oversee strategic planning, implementation, and execution of late-stage clinical trials per timelines, budget, and quality standards (including ICH GCP and local regulations)
- Develop and manage program project plans (protocols, budgets, timelines, enrollment, risk mitigation)
- Collaborate cross-functionally with Clinical Development, Regulatory Affairs, Biostatistics, and Program Leadership
- Provide operational expertise and strategic input into Clinical Development Plans (CDP)
- Ensure robust Phase 3 operational strategies (country/site mix, PR&R and Site Engagement, vendor strategy, risk-based and site monitoring)
- Serve as point of contact for CROs/vendors; oversee performance and adherence to contracts, timelines, and quality
- Ensure compliance with regulatory requirements, ICH-GCP, and company SOPs
- Support inspection readiness; guide Clinical Study Leads for inspections
- Contribute to/review clinical study documents (IB, IND, protocols, clinical study reports, NDA/MAA sections, IND/NDA updates, safety reports)
- Hire, train, and develop the KT-621 Phase 3 Clinical Operations team
Skills and experience you’ll bring:
- BA/BS, preferably health-related
- 12+ years clinical operations experience (pharma/biotech)
- Experience building/leading high-performing clinical operations teams
- Global regulatory/compliance expertise (US CRF, EU CTD, ICH GCP)
- Manage competing priorities in a fast-paced, high-pressure environment
- Strong communication, interpersonal, and problem-solving skills
Compensation:
- Anticipated base salary range: $235,000–$330,000; eligibility for annual bonus, equity participation, and comprehensive benefits.